Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 20 Oct 2022
TGA provisionally approves Moderna’s COVID-19 vaccine for use as a booster dose in individuals 12 years and older
20 October 2022 - On 19 October 2022, the TGA provisionally approved Moderna's COVID-19 vaccine, Spikevax (elasomeran), for use as ...
Posted by Michael Wonder on 19 Oct 2022
MSAC publishes outcome for Mackenzie's mission
19 October 2022 - Mackenzie’s Mission is a research study providing reproductive genetic carrier screening to up to 10,000 couples across ...
Posted by Michael Wonder on 19 Oct 2022
Fostamatinib disodium hexahydrate for the treatment of patients with refractory chronic immune thrombocytopenia
19 October 2022 - NICE has published evidence-based recommendations on the use of fostamatinib disodium hexahydrate for the treatment of ...
Posted by Michael Wonder on 19 Oct 2022
EMA recommends approval of Comirnaty and Spikevax COVID-19 vaccines for children from 6 months of age
19 October 2022 - The EMA’s CHMP has recommended extending the use of Comirnaty and Spikevax targeting the original strain ...
Posted by Michael Wonder on 19 Oct 2022
Advancing real world evidence program
19 October 2022 - As announced in the Federal Register notice published on 20 October 2022, the FDA is conducting an ...
Posted by Michael Wonder on 19 Oct 2022
Zanubrutinib for the treatment of patients with Waldenström’s macroglobulinaemia
19 October 2022 - NICE has published evidence-based recommendations on the use of zanubrutinib for the treatment of adults with ...
Posted by Michael Wonder on 19 Oct 2022
EMA recommends approval of second adapted Spikevax vaccine
19 October 2022 - The EMA’s CHMP has recommended authorising an adapted Spikevax COVID-19 vaccine targeting the Omicron subvariants BA.4 ...
Posted by Michael Wonder on 19 Oct 2022
Oestradiol hemifumarate with norethisterone acetate and relugolix for the treatment of moderate to severe symptoms of uterine fibroids
19 October 2022 - NICE has published evidence based recommendations on the use of oestradiol hemifumarate with norethisterone acetate and ...
Posted by Michael Wonder on 19 Oct 2022
FDA grants fast track designation to Tvardi Therapeutics’ TTI-101 for hepatocellular carcinoma
19 October 2022 - Tvardi Therapeutics today announced that its lead product, TTI-101, has been granted fast track designation by the ...
Posted by Michael Wonder on 19 Oct 2022
Pembrolizumab for adjuvant treatment of adults with renal cell carcinoma
19 October 2022 - NICE has published evidence-based recommendations on the use of pembrolizumab for the adjuvant treatment of adults ...
Posted by Michael Wonder on 19 Oct 2022
MSAC publishes agenda for February 2023 ESC meeting
19 October 2022 - The MSAC Secretariat has published a list of applications scheduled to be considered by the ESC ...
Posted by Michael Wonder on 19 Oct 2022
Senator Collins, Representative Eshoo decry Medicare coverage rejection of Alzheimer’s drugs
18 October 2022 - “It’s not CMS’ job to deny the use under the Medicare program of an FDA-approved drug.” – ...
Posted by Michael Wonder on 19 Oct 2022
Evusheld receives Health Canada approval for treatment of COVID-19
18 October 2022 - Evusheld significantly reduced risk of severe COVID-19 or death in TACKLE Phase 3 treatment trial. ...
Posted by Michael Wonder on 19 Oct 2022
Women call for 'life-changing' medicinal cannabis oil to be added to Pharmaceutical Benefits Scheme
18 October 2022 - At 79 years old, Trish Fisher still suffers from excruciating pain from a motorbike accident in her ...
Posted by Michael Wonder on 18 Oct 2022
3 in 10 uninsured Americans with diabetes may ration insulin
18 October 2022 - "Universal access to insulin, without cost barriers, is urgently needed." ...